Current location: Home > PRODUCTS > Next Generation Sequencing Series Products

PRODUCTS

Cardiotoxicity Prediction Of Breast Cancer Detection Kit

Cardiotoxicity Prediction Of Breast Cancer Detection Kit

Next Generation Sequencing

CE-IVD Certificate no.:No.MDD-SZ-XWA1-180523

Only for scientific research use in China



Breast cancer and Cardiotoxicity

Breast cancer is considered to be one of the woman health killers, which can cause high morbidity and mortality. Currently, chemotherapy is used as one of the most common treatments to breast cancer. However, it is reported that the traditional chemotherapy and target drugs against breast cancer could induce adversevisceral organs responses, especially the damage to the heart will induce angiocardiopathy which will greatly threaten the patient’s life and influence the livingquality. Cardiovascular mortality was highly suspected as the leading threaten confronting breast cancer patients in the next ten years after they had received chemotherapy or targeted drugs. Therefore, conduct gene detection prior to drug treatments will help the patients escape from serious side effects and extend the survival time of the patients.


 

Clinical Significance

This kit can detect 56 SNP loci in 38 genes related to cardiotoxicity of breast cancer treatment by one time, including: UGT1A,FANCD2,ABCC5,PIK3R,SLC22A7,VEGFA6,GSTA1,SLC22A16,ABCB1,CYP3A5,CYP3A4,SLC28A3,ESR2,

AKR1C3,CYP2C8,ABCC2,CAT,GSTP1,SLCO1B3,RARG,SLC22A17,TCL1A,MRP1,ABCC1,NQO1,CYBA,HER2,

RAPTOR,CYP2B6,CBR1,NCF4,RAC2,CYP2D6,CBR3,NOS3,ESR1,CELF4 and DPD. 


This kit is applicable for the patients with breast cancer who will be treated with certain drugs. The results can be used to predict efficacy and side effects of the drugs and guide the selection of suitable therapeutic treatments.



Breast cancer treatment related genes and indications for drug related cardiotoxicity


Gene Gene TypesIndications for Drug Related Cardiotoxicity (Partial)
ABCB1AA/AG/GG

Patients with A allele may have an increased risk of experiencing more metabolic time of 

doxorubicin. Therefore,their side effect lasting time may be longer compared to patients with 

the GG genotype.

AKR1C3CC/CG/GG

Patients with the GG genotype may have an increased risk of getting doxorubicin-induced 

hematotoxicity compared to patients with the CC/CG genotype. However, their PFS and OR 

may be longer.

CBR1GG/G A/AA

Patients with A allele may have an increased risk of having lower pharmacological activity of 

doxorubicincompared to the patients with the GG genotype.

CYBAAA/AG /GG

Patients with A allele may have an increased risk of getting doxorubicin-induced cardiotoxicity and may have adecreased survival rate compared to patients with the GG genotype.

CYP2C8TT/TC /CC

Patients with C allele may have an increased risk of experiencing severe peripheral

neurotoxicity induced by paclitaxel treatment compared to patients with the TT genotype.

CYP2D6CC/C T/TT

Patients with T allele may have a decreased risk of getting tamoxifen-induced hot flushes. 

However, they mayhave an increased risk of getting tamoxifen-induced side effects which will probably cause a drug withdrawal compared with patients to the CC genotype.

CYP3A5CC/C T/TT

Patients with T allele may have low affinity for taxanes. They may have an increased risk for

taxanes resistancecompared to patients with the CC genotype.

DPDCC/C T/TT

Patients with T allele may have an increased risk of getting fluorouracil-induced side effects 

compared to patientswith the CC genotype.

ESR2CC/C T/TT

Patients with the TT genotype may have a decreased risk of getting tamoxifen-induced hot 

flushes compared topatients with the C T/TT genotype.

FANCD2TT/TC /CC

Patients with C allele may have an increased risk of experiencing severe peripheral 

neurotoxicity induced by paclitaxel treatment compared to patients with the TT genotype.

GSTA1TT/TC /CC

Patients with T allele may have a decreased risk of getting cyclophosphamide-metabolized 

toxicity compared topatients with the CC genotype.

HER2CC/CG /GG

Patients with the CC genotype may have an increased risk of getting trastuzumab-induced 

side effects compared to patients with GG /GC genotype.

MRP1TT/TC /CC

Patients with gene T allele may have an increased risk of getting anthracyclines-induced left 

ventricular ejectiondysfunction compare to patients with the CC genotype.

NCF4GG/G A/AA

Patients with the AA genotype may have an increased risk of getting doxorubicin-induce 

cardiotoxicity compare to patients with the GG/GA genotype.

NQO1GG/G A/AA

Patients with A allele may have an increased risk of having lower pharmacological activity of 

doxorubicin compared to the patients with the GG genotype.

PIK3R1AA/AG/GG

Patients with G allele may have a decreased risk of getting hyperglycaemia compared to 

patients with the AA genotype. However, they may have an increased risk of leucopenia and 

lymphopenia.

RAC2TT/TA /AA

Patients with A allele may have an increased risk of getting doxorubicin-induced cardiotoxicity compare to patientswith the TT genotype.

RAPTORCC/C T/TT

Patients with T allele may have a decreased risk of getting non- infectious pneumonia 

compared to patients with the CC genotype.

RARGGG/G A/AA

Patients with A allele may have an increased risk of getting anthracyclines-induced 

cardiotoxicity compare to patients with the GG genotype.

SLC22A16TT/TC /CC

Patients with C allele may have an increased risk of experiencing more metabolic time of 

doxorubicin.Therefore, their side effect lasting time may be longer compared to patients with 

the TT genotype.

SLC22A7AA/AG /GG

Patients with G allele may have an increased risk of getting anthracyclines-induced 

cardiotoxicity comparedto patients with the AA genotype.

SLCO1B3AA/AG /GG

Patients with gene G allele may have an increased risk of getting docetaxel-induced 

leucopenia  ,neutropenia as well as marrow depression compared to patients with the AA 

genotype.

TCL1ACC/CG /GG

Patients with gene G allele may have an increased risk of getting arimedex-induced 

musculoskeletal adverse events compared to patients with the CC genotype.

VEGFA6CC/CG /GG

Patients with C allele may have an increased risk of getting bevacizumab-induced 

hypertension and other sideeffects compared to patients with the GG genotype.



Performance Parameter


Core

Technology


Products

Specification


Matched

Instrument


Sample requirements
Sample TypesQuantity

Preservation

 Condition

RingCap ®16 tests/kit

Ion torrent,

Illumina

peripheral

blood

10 mL4℃


Detection Process